Details for Patent: 11,911,518
✉ Email this page to a colleague
Which drugs does patent 11,911,518 protect, and when does it expire?
Patent 11,911,518 protects JORNAY PM and is included in one NDA.
This patent has thirty-seven patent family members in fourteen countries.
Drugs Protected by US Patent 11,911,518
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-001 | Aug 8, 2018 | RX | Yes | No | 11,911,518 | ⤷ Subscribe | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Subscribe | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-002 | Aug 8, 2018 | RX | Yes | No | 11,911,518 | ⤷ Subscribe | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Subscribe | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-003 | Aug 8, 2018 | RX | Yes | No | 11,911,518 | ⤷ Subscribe | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,911,518
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012230733 | ⤷ Subscribe | |||
| Australia | 2016228307 | ⤷ Subscribe | |||
| Australia | 2018202002 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
